| Title: |
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT |
| Authors: |
Nagler A.; Labopin M.; Blaise D.; Raiola A. M.; Corral L. L.; Bramanti S.; Sica S.; Kwon M.; Koc Y.; Pavlu J.; Kulagin A.; Busca A.; Rodriguez A. B.; Remenyi P.; Schmid C.; Brissot E.; Sanz J.; Bazarbachi A.; Giebel S.; Ciceri F.; Mohty M. |
| Contributors: |
Nagler, A.; Labopin, M.; Blaise, D.; Raiola, A. M.; Corral, L. L.; Bramanti, S.; Sica, S.; Kwon, M.; Koc, Y.; Pavlu, J.; Kulagin, A.; Busca, A.; Rodriguez, A. B.; Remenyi, P.; Schmid, C.; Brissot, E.; Sanz, J.; Bazarbachi, A.; Giebel, S.; Ciceri, F.; Mohty, M. |
| Publisher Information: |
BioMed Central Ltd |
| Publication Year: |
2023 |
| Subject Terms: |
De novo acute myeloid leukemia; Haploidentical allogeneic stem cell transplantation; Post-transplantation cyclophosphamide; Secondary acute myeloid leukemia; Transplantation outcomes |
| Description: |
We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide (PTCy). Seventeen hundred and eleven AML patients (sAML-231, de novo-1480) in first complete remission transplanted from 2010 to 2021, were included. Patients with de novo AML were younger, median age 55.8 versus 60.8years, p < 0.0001, had better transplantation comorbidity index (HCT-CI) ≥ 3 21.3% versus 40.8%, p < 0.0001 and Karnofsky performance status (KPS) with KPS ≥ 90 in 78% versus 68.5%, respectively, p = 0.002. The two patient groups did not differ with respect to gender, cytomegalovirus serostatus, and cell source. Median time from diagnosis to HaploSCT was 5.2 versus 4.9months, respectively, p = 0.005. Fewer sAML patients received myeloablative conditioning 35.1% versus 50.1%, p < 0.0001. Two hundred and eleven sAML and 410 de novo AML patients were included in the matched-pair analysis matching two de novo AML with each sAML. No significant difference was observed in any transplantation outcome parameter between the sAML versus de novo AML groups. Two-year non-relapse mortality and relapse incidence did not differ with HaploSCT for de novo versus sAML; 21.4% versus 21%, hazard ratio (HR) = 0.98, p = 0.9 and 23.4% versus 20.6%, HR = 0.92, p = 0.67, respectively. Two-year leukemia-free survival, overall survival, and graft-versus-host disease (GVHD)-free, relapse-free survival were also not different between the de novo AML and sAML groups 55.2% versus 58.4%, HR = 0.95, p = 0.67; 61.4% versus 66.4%, HR = 0.91, p = 0.51 and 46.3% versus 48.2%, HR = 0.92, p = 0.48, respectively. Similarly, the incidence of engraftment as well as acute and chronic GVHD was similar between the 2 cohorts. In conclusion, HaploSCT with PTCy may be able to overcome the bad prognosis of sAML as results are not significantly different to those of HaploSCT in de novo AML. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/37248463; info:eu-repo/semantics/altIdentifier/wos/WOS:000996785900001; volume:16; issue:1; numberofpages:15; journal:JOURNAL OF HEMATOLOGY & ONCOLOGY; https://hdl.handle.net/20.500.11768/164797 |
| DOI: |
10.1186/s13045-023-01450-4 |
| Availability: |
https://hdl.handle.net/20.500.11768/164797; https://doi.org/10.1186/s13045-023-01450-4; https://jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01450-4 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.716146A9 |
| Database: |
BASE |